7-hydroxystaurosporine has been researched along with Colonic Neoplasms in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, A; Jain, R; Jain, S; Khatik, R; Veer Kohli, D | 1 |
| Sturla, SJ; van Midwoud, PM | 1 |
| Bartek, J; Hasvold, G; Lukas, J; Petersen, L; Syljuåsen, RG | 1 |
| Bozko, P; Larsen, AK; Raymond, E; Skladanowski, A | 1 |
| Kohn, KW; La Rose, J; Pommier, Y; Takemura, H; Yu, Q; Zhang, H | 1 |
| Chan, UP; Chen, GG; Lee, JF; Leung, KL; Wang, SH | 1 |
| Schwartz, GK; Tse, AN | 1 |
| Bhonde, MR; Daniel, PT; Hanski, C; Hanski, ML; Kohno, K; Magrini, R; Moorthy, D; Müller, A; Sausville, EA; Wiegand, P; Zeitz, M | 1 |
| Brown, S; Chen, EX; Dancey, JE; Hirte, HW; Hotte, SJ; Moore, M; Oza, A; Pond, GR; Winquist, EW | 1 |
| Aladjem, MI; Aune, GJ; Bonner, WM; Furuta, T; Hayward, RL; Kohn, KW; Meng, LH; Pommier, Y; Takemura, H | 1 |
| Eastman, A; Fan, S; O'Connor, PM; Sausville, EA; Wang, Q; Worland, PJ | 1 |
| Pommier, Y; Shao, RG; Shimizu, T | 1 |
| Chambers, TC; Drake, RR; Jones, KE; McMasters, RA; Moyer, MP; Pitlyk, K; Saylors, RL; Wilbert, TN | 1 |
1 trial(s) available for 7-hydroxystaurosporine and Colonic Neoplasms
| Article | Year |
|---|---|
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Salivary Gland Neoplasms; Staurosporine; Survival Analysis; Topotecan | 2006 |
12 other study(ies) available for 7-hydroxystaurosporine and Colonic Neoplasms
| Article | Year |
|---|---|
Minicapsules encapsulating nanoparticles for targeting, apoptosis induction and treatment of colon cancer.
Topics: Animals; Apoptosis; Capsules; Caspase 3; Cell Line, Tumor; Cell Survival; Chitosan; Colonic Neoplasms; DNA Fragmentation; Folic Acid; Mice; Mice, Inbred C57BL; Nanoparticles; Staurosporine; Xenograft Model Antitumor Assays | 2019 |
Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor.
Topics: Antineoplastic Agents, Alkylating; Cell Survival; Chromatography, High Pressure Liquid; Colonic Neoplasms; DNA Adducts; DNA Repair; DNA Repair Enzymes; Drug Synergism; HT29 Cells; Humans; Sesquiterpenes; Spectrometry, Mass, Electrospray Ionization; Spiro Compounds; Staurosporine | 2013 |
p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors.
Topics: Cell Cycle; Cell Death; Cell Survival; Checkpoint Kinase 1; Colonic Neoplasms; Genes, p53; HCT116 Cells; Humans; Neoplasms; Nervous System Neoplasms; Protein Kinases; Radiation, Ionizing; Staurosporine; Tumor Suppressor Protein p53 | 2010 |
Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Cell Cycle; Colonic Neoplasms; Etoposide; Humans; Staurosporine; Topoisomerase Inhibitors; Tumor Suppressor Protein p53 | 2002 |
UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Checkpoint Kinase 1; Checkpoint Kinase 2; Colonic Neoplasms; Enzyme Activation; Enzyme Inhibitors; G2 Phase; Gamma Rays; Humans; Mitosis; Phosphorylation; Precipitin Tests; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2002 |
Induction of colon cancer cell death by 7-hydroxystaurosporine (UCN-01) is associated with increased p38 MAPK and decreased Bcl-xL.
Topics: Apoptosis; bcl-X Protein; Caspase 3; Caspases; Colonic Neoplasms; Dose-Response Relationship, Drug; HT29 Cells; Humans; Mitogen-Activated Protein Kinases; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Receptors, Cytoplasmic and Nuclear; Staurosporine; Transcription Factors | 2003 |
Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastroph
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; DNA Damage; DNA Replication; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; G2 Phase; HCT116 Cells; Humans; Irinotecan; Microscopy, Fluorescence; Mitosis; S Phase; Staurosporine; Topoisomerase I Inhibitors; Transfection; Tumor Suppressor Protein p53 | 2004 |
The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma; Colonic Neoplasms; Cyclin-Dependent Kinases; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; STAT3 Transcription Factor; Staurosporine; Trans-Activators; Tumor Cells, Cultured | 2005 |
p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine.
Topics: Aphidicolin; Apoptosis; Chromosome Breakage; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; DNA; DNA Damage; DNA Repair; DNA Replication; DNA Topoisomerases, Type I; HCT116 Cells; Histones; Humans; In Situ Nick-End Labeling; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; S Phase; Staurosporine; Tumor Suppressor Protein p53 | 2006 |
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Topics: Alkaloids; Antineoplastic Agents; Burkitt Lymphoma; CDC2 Protein Kinase; Cell Division; Cell Survival; Cisplatin; Colonic Neoplasms; Cyclin B; Cyclin B1; Cyclins; Drug Synergism; Flow Cytometry; G2 Phase; Gamma Rays; Genes, p53; Humans; Immunoblotting; Mitotic Index; Mutation; Precipitin Tests; Radiation Dosage; Staurosporine; Tumor Cells, Cultured | 1996 |
7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53.
Topics: Adenocarcinoma; Alkaloids; Apoptosis; Caspase 3; Caspases; CDC2 Protein Kinase; Colonic Neoplasms; Cyclin B; Cyclin B1; Cyclins; Cycloheximide; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA Fragmentation; Enzyme Inhibitors; HL-60 Cells; HT29 Cells; Humans; Lamin Type B; Lamins; Leukemia, Myeloid, Acute; Nuclear Proteins; Poly(ADP-ribose) Polymerases; Protein Kinase C; Protein Synthesis Inhibitors; Serine Proteinase Inhibitors; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |
Two-drug combinations that increase apoptosis and modulate bak and bcl-X(L) expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinase.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Butyrates; Camptothecin; Caspase 3; Caspases; Cell Survival; Colonic Neoplasms; Drug Interactions; Ganciclovir; Humans; Membrane Proteins; Paclitaxel; Peptide Hydrolases; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Simplexvirus; Staurosporine; Thymidine Kinase; Transfection; Tumor Cells, Cultured | 2000 |